Cargando…

Comparing direct oral anticoagulants and vitamin K antagonist use in morbidly obese patients with venous thromboembolism: A single center retrospective cohort study

Introduction: Limited data exists on the safety and efficacy of direct‐acting oral anticoagulants (DOAC) use in morbidly obese patients with venous thromboembolism (VTE). Given the benefits of DOAC use over vitamin K antagonists (VKAs), in terms of monitoring requirements, and dietary and drug inter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scott, Lia C., Li, Juan, Cafuir, Lorraine A., Gaddh, Manila, Kempton, Christine L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175804/ https://www.ncbi.nlm.nih.gov/pubmed/35846040 http://dx.doi.org/10.1002/jha2.418

Ejemplares similares

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
por: Patel, Raj
Publicado: (2016)

Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous thromboembolism: A meta-analysis
por: Zhang, Hongxia, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
por: Sun, Ke-Xin, et al.
Publicado: (2021)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism: a meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2021)

Clinical Utilization and Cost of Thrombophilia Testing in Patients with Venous Thromboembolism
por: Gaddh, Manila, et al.
Publicado: (2020)

Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
por: Park, Dae Yong, et al.
Publicado: (2023)

Physician perceptions and use of reduced‐dose direct oral anticoagulants for extended phase venous thromboembolism treatment
por: Groat, Danielle, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
por: Liu, Zhi-Yan, et al.
Publicado: (2022)

Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
por: Yoon, Dongwon, et al.
Publicado: (2023)

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
por: Goldstein, Patrick, et al.
Publicado: (2013)

Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism
por: Keita, Ingre, et al.
Publicado: (2017)

County-Level Social Vulnerability Is Associated with Increased Risk for Venous Thromboembolism in COVID-19
por: Meena, Richard A., et al.
Publicado: (2021)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

COVID-19–associated venous thromboembolism portends worse survival
por: Meena, Richard A., et al.
Publicado: (2021)

Comparison Between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism
por: Chen, Dong-Yi, et al.
Publicado: (2021)

D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-vitamin K anticoagulants
por: Legnani, Cristina, et al.
Publicado: (2019)

Comparison of Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations
por: Gaddh, Manila, et al.
Publicado: (2023)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials
por: Wang, Wei, et al.
Publicado: (2020)

The Coronavirus Disease 2019 Likelihood of Thrombosis Calculator: Predicting Venous Thromboembolism Risk in Hospitalized Patients With Coronavirus Disease 2019
por: Meena, Richard A., et al.
Publicado: (2021)

Anticoagulation in the obese patient with COVID-19-associated venous thromboembolism
por: McCormick, John Peter, et al.
Publicado: (2021)

New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
por: Mekaj, Ymer H, et al.
Publicado: (2015)

Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation
por: Hong, Keun-Sik
Publicado: (2019)

Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis
por: Katel, Anjan, et al.
Publicado: (2021)

Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes
por: Larsen, Torben Bjerregaard, et al.
Publicado: (2014)

Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register
por: Palareti, Gualtiero, et al.
Publicado: (2020)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism
por: Bromley, Andrew, et al.
Publicado: (2018)

A Comparison among Nonvitamin K Antagonist Oral Anticoagulants in Asian Patients with Venous Thromboembolism: A Multi-Institutional Study
por: Tsai, Ming-Lung, et al.
Publicado: (2022)

The Use of Direct Oral Anticoagulants in the Management of Venous Thromboembolism in Patients With Obesity
por: Younis, Moustafa, et al.
Publicado: (2020)

Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
por: Mearns, Elizabeth S, et al.
Publicado: (2014)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
por: Carney, Brian J., et al.
Publicado: (2021)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Venous thromboembolism in women
por: Peclat, Ana Paula Rolim Maia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iv7basam304s7bibmdi1h8pf4n